Mild cognitive impairment of uncertain or unknown etiology
Methodology & AI Transparency ⓘ
Mild cognitive impairment of uncertain or unknown etiology Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Mild cognitive impairment of uncertain or unknown etiology (ICD-10-CM G31.84), Alzheimer, Dementia & Memory Health protocols prioritize standardized neuropsychological testing in Mild cognitive impairment of uncertain or unknown etiology (G31.84: (MoCA/MMSE)) paired with baseline and interval MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code G31.84 categorizes Mild cognitive impairment of uncertain or unknown etiology under Alzheimer, Dementia & Memory Health.
- 3 Typical cash cost range: Primary evaluation for Mild cognitive impairment of uncertain or unknown etiology incorporates standardized neuropsychological testing in Mild cognitive impairment of uncertain or unknown etiology (G31.84: (MoCA/MMSE)) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Mild cognitive impairment of uncertain or unknown etiology: maintaining MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) within >= 26 / 30 (G31.84).
Ask our AI Specialists anything about Mild cognitive impairment of uncertain or unknown etiology
What Is Mild cognitive impairment of uncertain or unknown etiology?
For patients presenting with Mild cognitive impairment of uncertain or unknown etiology (ICD-10-CM G31.84), Alzheimer, Dementia & Memory Health protocols prioritize standardized neuropsychological testing in Mild cognitive impairment of uncertain or unknown etiology (G31.84: (MoCA/MMSE)) paired with baseline and interval MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Mild cognitive impairment of uncertain or unknown etiology (code G31.84) is cerebral small-vessel microvascular in Mild cognitive impairment of uncertain or unknown etiology (G31.84: hypoperfusion), which Alzheimer, Dementia & Memory Health clinicians address while surveilling MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) (>= 26 / 30 (G31.84)).
Common Symptoms & Clinical Signs
- • Presentation of Mild cognitive impairment of uncertain or unknown etiology (G31.84): short-term recall difficulty in Mild cognitive impairment of uncertain or unknown etiology (G31.84: for recent conversations,)
- • Secondary Mild cognitive impairment of uncertain or unknown etiology clinical sign: word-finding pauses, difficulty in Mild cognitive impairment of uncertain or unknown etiology (G31.84: managing multi-step finances,)
- • Symptom flares in Mild cognitive impairment of uncertain or unknown etiology correlating with MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) deviation outside >= 26 / 30 (G31.84)
- • Functional memory & cognition impact requiring standardized neuropsychological testing in Mild cognitive impairment of uncertain or unknown etiology (G31.84: (MoCA/MMSE)) evaluation (G31.84)
Mild cognitive impairment of uncertain or unknown etiology Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.84 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Mild cognitive impairment of uncertain or unknown etiology (G31.84: Score) | >= 26 / 30 (G31.84) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Mild cognitive impairment of uncertain or unknown etiology (G31.84: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.84) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Mild cognitive impairment of uncertain or unknown etiology (G31.84: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.84) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mild cognitive impairment of uncertain or unknown etiology
Treatment selection for Mild cognitive impairment of uncertain or unknown etiology depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mild cognitive impairment of uncertain or unknown etiology)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| GLP-1RA vs. Placebo: Which Works Better for Heart failure and mildly reduced or preserved ejection fraction? GLP-1RA reduce HF exacerbations and can play a role in reducing hospitalizations, improving patient's functional status, and significantly impacting the global healthcare burden of HF. International journal of cardiology • 2025-11-01 • Meta-Analysis | N = 4,474 | 99/100 | PMID 40623630 ↗ |
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the: What a 13,026-Participant Study Found We explore the emerging role of the nonsteroidal MRA finerenone as a new therapeutic opportunity to improve the risk of adverse heart and blood vessel outcomes in patients with HF and mildly reduced or preserved ejection. American journal of cardiovascular drugs : drugs, devices, and other interventions • 2025-07-15 • Phase III Randomized Trial | N = 13,026 | 96/100 | PMID 40055303 ↗ |
| New Insights on Efficacy of finerenone in patients with heart failure and mildly reduced or: What a 3,497-Participant Study Found Among patients with HFpEF/HFmrEF in FINEARTS-HF, higher baseline HR was associated with a higher risk of the primary outcome in patients with SR but not in those with AF. European journal of heart failure • 2026-05-02 • Phase III Randomized Trial | N = 3,497 | 96/100 | PMID 41771075 ↗ |
| Check Your Medicine Cabinet: Family Farmstead Dairy Announces Recall of Raw Mild Cheddar Cheese Due to Potential E. c WORCESTER, NY, October 15, 2026 - Family Farmstead Dairy of Worcester, NY is recalling specific lot of cheddar cheese because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with FDA Drug Recalls • 2026-10-15 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-2412744266 ↗ |
Mild cognitive impairment of uncertain or unknown etiology Patient Community & “People Like Me” Threads
Filter Mild cognitive impairment of uncertain or unknown etiology community threads and patient logs by age, biological sex, dosage, and treatment duration.